Faron Pharmaceuticals' (LON:FARN) chief executive Dr Markku Jalkanen joins Proactive London's Katie Pilbeam about groundbreaking data from a clinical study of its Bexmarilimab cancer treatment.
The company announced promising new data from its bexmarilimab MATINS study, reporting combined headline data from 141 evaluable patients enrolled in the completed Part I and ongoing Part II of the study.
He also goes on to explain their agreement for the rights to a US patent covering the manufacturing of its interferon-beta 1a drug Traumakine.
